Skip to main content

Research News

  • New omicron BA.2.75 is as susceptible to antibodies as the currently dominant variant : Researchers

    In a recent study researchers from Karolinska Institutet, among others, have characterised the new omicron variant BA.2.75, comparing its ability to evade antibodies against current and previous variants. The study, published in the journal The Lancet Infectious Diseases, suggests that BA.2.75 is not more resistant to antibodies than the currently dominating BA.5, which is positive news.

  • Low testosterone may increase risk of COVID-19 hospitalization for men

    Men with low testosterone who develop COVID-19 are at elevated risk of becoming seriously ill and ending up in the hospital, according to a study by researchers at Washington University School of Medicine in St. Louis and Saint Louis University School of Medicine.

  • Oral insulin no more delusion, Scientists develops insulin tablet

    ​Breakthrough discovery made by University of British Columbia scientists by developing an oral insulin tablet which will work as replacement for daily insulin injections.

    Research from Indian roots and currently involved in research at  University of British Columbia Dr. Anubhav Pratap Singh’s team developed a different kind of tablet that isn’t made for swallowing, but instead mouth-dissolving which dissolves when placed between the gum and cheek.

  • Dolutegravir-based antiretroviral therapies for HIV-1 effective in pregnancy

    Dolutegravir-based antiretroviral therapies (ART) for HIV-1 are more effective for pregnant people than some other ART regimens commonly used in the U.S. and Europe, according to a study led by Harvard T.H. Chan School of Public Health researchers.

  • Simple blood test predicts neurotoxic complications of CAR-T cell therapy

    A new study from Washington University School of Medicine in St. Louis suggests a simple blood test administered before CAR-T cell treatment is initiated may identify which patients are predisposed to developing neurotoxic side effects after CAR-T cell therapy. Severe side effects can include seizures, brain swelling and strokes. Evidence of a stroke (red arrows) is seen on this MRI scan of the brain of a patient who developed neurotoxic side effects after CAR-T cell therapy.

  • Ingeniously developed cervical cancer vaccine to hit the market soon

    Cervavac was launched on September 1, 2022, after the Drugs Controller General of India had granted market authorization to Serum Institute of India. Cervavac is developed by a partnership of DBT and BIRAC with the Bill and Melinda Gates Foundation, supported by Serum Institute of India for the indigenous development of quadrivalent vaccines.

    Dr Jitendra Singh said, this affordable and cost effective vaccine marks an important day for DBT and BIRAC as it takes India a step closer to PM Modi’s vision of Atmanirbhar Bharat.

  • Outdated cancer drug in combination found effective against lung cancer

    An experimental combination of two drugs halts the progression of small cell lung cancer, the deadliest form of lung cancer, according to a study in mice from researchers at Washington University School of Medicine in St. Louis, Grenoble Alpes University in Grenoble, France, and The University of Texas MD Anderson Cancer Center in Houston.

  • Anti Malarial medicine has potential to kill MDR Bacteria

    University researchers have found a naturally occurring compound, known as hydroquinine, has bacterial killing activity against several microorganisms.

    Antimicrobial resistance has become one of the greatest threats to public health globally. It occurs when bacteria, viruses, fungi and parasites change over time and no longer respond to medicines, making it difficult to treat infections. Because of this, there is a pressing need for the development of new antimicrobial drugs to combat infections.

  • New therapeutic prospect for preeclampsia

    Preeclampsia is a condition that affects the placenta during pregnancy and is dangerous for both the fetus and the mother. Scientists from the Institut Pasteur, Inserm and the CNRS have proposed a new therapy, tested in two rodent models, that corrects the defects identified in placental cells, and restores placental and fetal weight. The treatment successfully lowers blood pressure in the mother and resolves the characteristic preeclampsia symptoms of excess protein in urine and cardiovascular abnormalities.

  • Genetic Testing Before Pregnancy Detects up to Half of the Risk

    Are would-be parents carrying a genetic risk of serious illnesses that they could potentially pass on to their children? In the USA, doctors recommend that couples have genetic screening before trying to conceive. Researchers at the University of Zurich have now shown that a maximal variant of this test detects the risk in 44 percent of couples who are related by blood, and in just 5 percent of other couples. Non-hereditary newly acquired mutations are a major reason for the reduced detection rate in the latter.

Subscribe to Research News